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Objective To examine the association between chronic immune-mediated diseases 
(rheumatoid arthritis, systemic lupus erythematosus, or the following chronic immune-
mediated inflammatory diagnoses groups: inflammatory bowel diseases, inflammatory 
polyarthropathies, systemic connective tissue disorders and spondylopathies) and the 6-
year coronary artery disease, stroke, cardiovascular disease incidence and overall 
mortality; and to estimate the population attributable fractions for all four end-points for 
each chronic immune-mediated inflammatory disease. 
Methods  Cohort study of individuals aged 35-85 years, with no history of 
cardiovascular disease from Catalonia (Spain). The coded diagnoses of chronic 
immune-mediated diseases and cardiovascular diseases were ascertained and registered 
using validated codes, and date of death was obtained from administrative data. Cox 
regression models for each outcome according to exposure were fitted to estimate 
hazard ratios (HR) in two models: (1) after adjustment for sex, age, cardiovascular risk 
factors and (2) further adjusted for drug use. Population attributable fractions were 
estimated for each exposure.  
Results  Data were collected from 991,546 participants. The risk of cardiovascular 
disease was increased in systemic connective tissue disorders [Model 1: HR=1.38 (95% 
confidence interval=1.21-1.57) and 2: HR=1.31 (1.15-1.49)], rheumatoid arthritis 
[HR=1.43 (1.26-1.62) and HR=1.31 (1.15-1.49)] and inflammatory bowel diseases 
[HR=1.18 (1.06-1.32) and HR=1.12 (1.01-1.25)]. The effect of anti-inflammatory 
treatment was significant in all instances [HR=1.50 (1.24-1.81); HR=1.47 (1.23-1.75); 
HR=1.43 (1.19-1.73), respectively]. The population attributable fractions for all three 
disorders were 13.4%, 15.7%, and 10.7%, respectively.  
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Conclusion  Systemic connective tissue disorders and rheumatoid arthritis conferred the 
highest cardiovascular risk and population impact, followed by inflammatory bowel 
diseases.  
Keywords Cardiovascular disease, Inflammation, Arthritis, Connective Tissue 





What is already known on this subject? 
Individuals diagnosed chronic immune-mediated inflammatory diseases present with 
increased CVD risk.  
There are no comparable indicators to ascertain the cardiovascular risk associated with 
each chronic immune-mediated inflammatory disease due to the different inclusion 
criteria used in previous publications. 
 
What might this study add? 
Cardiovascular events and overall mortality risk was particularly pronounced in 
individuals diagnosed with systemic connective tissue disorders [HR=1.31 (95% 
confidence interval=1.15-1.49) and HR=1.30 (1.17-1.44), respectively] and rheumatoid 
arthritis [HR=1.31 (1.15-1.49) and HR=1.31 (1.18-1.46), respectively]. This risk was 
not explained by the higher prevalence of cardiovascular risk factors, nor by the use of 
DMARDs and anti-inflammatory drugs. 
 
How might this impact on clinical practice? 
The development of new tools for the prediction of cardiovascular events, which could 






The primary prevention of cardiovascular diseases (CVD) is a paramount priority of the 
public health agenda because it is the main cause of death in the developed world and is 
increasing alarmingly in developing countries.1 The common basis of CVD is 
atherosclerosis, an inflammatory degenerative process present throughout a person’s 
lifetime.2  The pathogenesis of CVD in patients with chronic immune-mediated 
inflammatory diseases (CIID) is multi-factorial and is thought to result from an 
interaction of inflammation, metabolic factors, therapy, and disease-related factors.3  
Individuals diagnosed with inflammatory bowel diseases,4 rheumatoid arthritis,5 
systemic lupus erythematosus,6 systemic sclerosis,7 or ankylosing spondylitis8 have 
shown an increased CVD risk. However, straightforward comparison of the studies is 
difficult owing to the different inclusion criteria used. Better understanding of the 
association between these conditions and cardiovascular morbidities can help in early 
assessment and management of risk factors and may help to improve long-term 
outcomes in patients with CIID.  
The objectives of the study were: (1) to ascertain whether 6-year risk of coronary 
artery disease, stroke, CVD incidence and overall mortality are associated with the 
diagnosis of rheumatoid arthritis, systemic lupus erythematosus, or the following CIID 
diagnoses groups: inflammatory bowel diseases, inflammatory polyarthropathies, 
systemic connective tissue disorders, and spondylopathies; and (2) to estimate the 
population-based burden of coronary artery disease, stroke, CVD, and mortality 







The System for the Development of Research in Primary Care (SIDIAP) is an electronic 
medical records database derived from general practices of the Catalan Institute of 
Health in Catalonia (Spain). Data on approximately 5.8 million patients are recorded by 
general practitioners as part of patients’ clinical records. Since approximately 80% of 
the population is registered with a general practitioner of the Catalan Institute of Health, 
SIDIAP is considered representative of the population in Catalonia.9 SIDIAP includes 
demographics, consultations with general practitioners, diagnoses, clinical variables, 
prescriptions, referrals to specialists, laboratory test results, and medications obtained 
from pharmacists. The International Classification of Diseases 10th Edition (ICD-10) is 
used to code diagnoses and the Anatomical Therapeutic Chemical (ATC) Classification 
System is used for the classification of drugs. SIDIAP is also linked with hospital 
admissions data. 
SIDIAPQ is the subsample of individuals assigned to the 40% of general 
practitioners periodically selected to provide researchers with the best quality registry 
data. The methodology for selecting this subsample, which is representative of the 
Catalan population in terms of sex and age distribution, has been explained in detail 
elsewhere.9 The SIDIAP database has been validated for the study of the epidemiology 
of CVD by comparing the observed prevalence of cardiovascular risk factors and their 
association with the incidence of CVD with those of an epidemiological population-
based study with a standardized methodology. The present study was approved by the 





We conducted a cohort study of individuals included in SIDIAPQ. The inclusion period 
spanned 1 January 2007 through 31 December 2012. Participants were 35 to 85 years 
old and those who had a record documenting a past history of myocardial infarction, 
angina, stroke, transient ischemic attack, intermittent claudication or coronary 
revascularization procedures prior to the inclusion were excluded. Patients were 
followed up until they experienced the outcomes of interest, died, left the SIDIAPQ 
database (e.g. change of address) or the follow-up ended (31 December 2012), 
whichever came first. 
 
Definition of chronic immune-mediated inflammatory disease 
A pre-specified list of ICD-10 codes, set a priori and based on previous work in the 
field,10 11 was used to screen SIDIAPQ records in order to identify all patients with CIID 
and classify them in four groups: (1) inflammatory bowel disease, (2) inflammatory 
polyarthropathies, (3) systemic connective tissue disorders, and (4) spondylopathies (see 
the disorders included in each group in Supplementary Table 1). In addition, a 
complementary analysis was performed for the most prevalent single diagnoses: (5) 
rheumatoid arthritis and (6) systemic lupus erythematosus. We included individuals 
without a registered diagnosis who required a continued prescription for a medication 
that would normally be used to treat inflammatory bowel disease, rheumatoid arthritis 
or systemic lupus erythematosus, based on evidence-based recommendations.12- 15 If an 
individual presented with more than two diagnoses, we considered the oldest one for the 
purpose of this analysis. Individuals who developed CIID during follow-up were 
considered non-exposed. Since the CIID considered in this study have physical features, 
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adverse prognosis and the database has been previously validated10 11 diagnoses are 
expected to be accurately recorded.  
 
Identification of outcomes 
The end-points considered were: (1) coronary artery disease: incident myocardial 
infarction or angina; (2) incident stroke; (3) cardiovascular disease: coronary artery 
disease or stroke; and (4) all-cause mortality (Supplementary Table 2). All end-points 
were identified from the SIDIAP and Hospital Discharge registries. The methodology 
for case-finding used in the SIDIAP database has shown high validity and good 
representativeness of the population for use in epidemiological studies of CVD [9]. 
 
Assessment of covariables 
Data were obtained from the database on sex, age, systolic and diastolic blood pressure, 
glucose, triglycerides, total, high density lipoprotein (HDL) and low-density lipoprotein 
(LDL) cholesterol, glycaemia, weight, and height at baseline.  
Presence of cardiovascular risk factors was extracted from electronic records based 
on the presence of relevant codes (which follow the recommendations of the clinical 
practice guidelines of the Catalan Institute of Health) with a date prior to the inclusion 
of each participant: (1) Diabetes mellitus: ICD-10 categories E11, E12, E14, and 
subcategories thereof; (2) Hypertension: ICD-10 categories I10, I15, and subcategories 
thereof; (3) Hypercholesterolemia: ICD-10 category E78 and its subcategories, except 
for E78.3 and E78.6; (4) Smoking: ICD-10 category F17 for smokers or Z72.0 for 
exsmokers and (5) Obesity: ICD-10 category E66 and subcategories except for E66.1 
and E66.2 [9]. Coronary artery disease risk was estimated in participants aged 35 to 74 
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years with the Framingham-REGICOR function (Girona Heart Registry [Registre 
Gironí del Cor]) validated for the Spanish population.16 Participants were categorized 
into three treatment groups: disease-modifying anti-rheumatic drugs including biologic 
therapies (DMARD), anti-inflammatory drugs (i.e. non-steroidal anti-inflammatory 
drugs, glucocorticoids, other non-inflammatory drugs), and non-users of DMARD and 
anti-inflammatory drugs. Lipid-lowering and antihypertensive treatments were also 
considered. The drugs included in each group are summarized in Supplementary Table 
3, 4 and 5. 
 
Statistical analysis 
We used 10 multiple imputations by chained equations17 to replace missing baseline 
values for total, HDL and LDL cholesterol, triglycerides, glycaemia, systolic and 
diastolic blood pressure, height, weight and MEDEA index (a deprivation index 
designed to capture sex-related inequalities). In addition to incorporating the missing-at-
random assumption, we compared case-complete results alone with the multiple 
imputations as a sensitivity analysis.  
Continuous variables were summarized as mean (standard deviation) or median 
[interquartile range] when their distribution departed from normal, and categorical 
variables as proportions. The incidence of coronary artery disease, stroke and CVD 
events and overall mortality was estimated. We plotted the Kaplan-Meier curves for all 
four end-points by CIID diagnoses and in population with no CIID and we performed 
log-rank tests to estimate the differences between each diagnosis and CIID-free 
individuals. Bonferroni correction for multiple comparisons was applied, considering as 
significant a p-value <0.002.  
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To assess the association between the CIID diagnoses and the 6-year incidence of 
coronary artery disease, stroke and CVD events or death, we adjusted two Cox 
regression models for each outcome. The first was adjusted for sex, age, systolic and 
diastolic blood pressure, total and HDL cholesterol, diabetes and smoking. The second 
was further adjusted for lipid-lowering, antihypertensive and rheumatic-specific drug 
use divided in three categories. The proportionality assumption was tested for all 
models (Supplementary Table 6). To test the robustness of case-definition, we 
performed several sensitivity analyses. In the first, we excluded patients with no record 
of a diagnosis but who required continued prescription of a medication normally used to 
treat inflammatory bowel disease, rheumatoid arthritis, or systemic lupus 
erythematosus, based on evidence-based recommendations. The second sensitivity 
analysis excluded those individuals who were receiving anti-inflammatory treatment 
(NSAIDs or DMARDs) before the CIID diagnosis. The third excluded those individuals 
with chronic diseases that may be related with both inflammation and cardiovascular 
risk (e.g., chronic kidney disease, sleep disorders, and liver disease). Also, as a 
sensitivity analysis, model 2 was adjusted using the Fine and Gray method for coronary 
artery disease, stroke and CVD outcomes and considering death as a competing event.  
Finally, to estimate the burden of CVD and mortality attributable to each CIID, the 
PAF were estimated for all four end-points, using Levin's formula. We used the adjusted 
hazard ratios (HR) according to model 2 and the prevalence of every CIID diagnosis 







We included 991,546 individuals in our analysis, 467,494 (47.1%) men, mean age 53 
years (standard deviation=13). Inflammatory polyarthropathies was the most prevalent 
CIID diagnosis (2.3%), followed by inflammatory bowel diseases (1.0%), systemic 
connective tissue disorders (0.5%) and spondylopathies (0.2%) (Figure 1). Additionally, 
5552 (0.6%) presented with rheumatoid arthritis and 664 (0.07%) with systemic lupus 
erythematosus. Individuals with CIID were older, and more often presented with 
diabetes, hypertension, dyslipidemia, obesity and higher 10-year cardiovascular risk 
than those without CIID.  Finally, the individuals with CIID were more frequently on 
treatment with statins, aspirin and DMARDs (Table 1).  
Annual incidence rates for all end-points showed significantly higher rates in those 
diagnosed with CIID (Table 2). Additionally, the Kaplan-Meier curves showed 
significantly lower disease-free time (i.e., coronary artery disease, cerebrovascular 
diseases and CVD) and survival for all CIID diagnoses compared with CIID-free 
population, except for systemic lupus erythematosus and spondylopathies. Indeed, the 
latter only presented with higher risk for death (Figure 2).  
The multivariable models showed that systemic connective tissue disorders and 
rheumatoid arthritis increased the risk of all end-points considered, particularly 
coronary artery disease for the first [HR=1.37; (95% confidence interval: 1.15-1.65)] 
and stroke for the latter [HR=1.33 (1.11-1.60)]. Among individuals with systemic lupus 
erythematosus, only the risk of mortality was significantly higher [HR=1.50; (1.03-
2.18)], even though the group in which this disease is included (i.e. systemic connective 
tissue disorders) conferred an increased risk for all end-points. On the other hand, the 
group of inflammatory polyarthropathies only showed a marginally significant 
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association with stroke [HR=1.09; (0.99-1.19)]. Finally, inflammatory bowel diseases 
had a significant association with stroke and with overall mortality [HR=1.23; (1.06-
1.43) and HR=1.64; (1.51-1.76), respectively] (Figure 3). No relevant differences were 
found between the main analysis and any sensitivity analysis performed (Supplementary 
Tables 7-12). 
The CIIDs with significant population impact on coronary artery disease, stroke and 
CVD were systemic connective tissue disorders (15.6%, 9.1%, and 13.4%, respectively) 
and rheumatoid arthritis (14.4%, 16.5%, and 15.7%, respectively). In addition, 
inflammatory bowel diseases presented significant PAF for stroke (18.7%) and for 
cardiovascular diseases (10.7%). Finally, the population impact on overall mortality was 
significant for all CIIDs, except for the spondylopathies, although the magnitude ranged 
from 39.0% for inflammatory bowel diseases to 3.4% for systemic lupus erythematosus 
(Figure 4).  
 
DISCUSSION 
Diagnoses of CIID confer an increased risk of cardiovascular disease and overall 
mortality. This risk was particularly pronounced in individuals diagnosed with systemic 
connective tissue disorders and rheumatoid arthritis. Overall mortality risk was 
increased in both groups of diseases. This greater risk was not explained by aging, the 
higher prevalence of cardiovascular risk factors observed in CIID individuals, nor by 
the use of DMARDs and anti-inflammatory drugs, which may have a role in the 
modulation of cardiovascular risk. Indeed, the differences in the estimated 
cardiovascular risk did not reflect higher incidence in individuals with CIID compared 
to those without, pointing out the effect of other variables not included in such 
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estimates. Additionally, inflammatory bowel diseases raised the risk of stroke and the 
overall mortality risk. 
 
Risk of cardiovascular disease in chronic immune-mediated inflammatory disease 
Individuals with CIID were older and had a worse cardiovascular risk factor profile; 
however, the multivariable analysis adjusted for the relevant variables showed an added 
risk not explained by these cardiovascular risk-related variables. A previous study, 
which also analyzed data from electronic medical records, showed similar coronary 
artery disease and stroke incidence in individuals with systemic connective disorders, 
inflammatory polyarthropathies, and inflammatory bowel diseases.18 Additionally, we 
performed the same analysis separately for rheumatoid arthritis and for systemic lupus 
erythematosus, the most prevalent diseases within both groups, and therefore the most 
reported in the literature. As previously described, rheumatoid arthritis showed a 
significant risk in all four end-points, even after adjustment for drug therapy.19 
Lazzerini et al. pointed out that a higher risk of rhythm disturbances, particularly 
tachiarrythmias, in such individuals may significantly contribute to the high 
cardiovascular morbidity and mortality.20 Systemic lupus erythematosus only showed a 
significant association with overall mortality. However, the systematic review 
performed by Schoenfeld et al. showed that systemic lupus erythematosus at least 
doubled cardiovascular risk.21 Concurring with Andersohn et al., individuals with 
inflammatory bowel diseases presented higher risk of stroke.22 On the other hand, the 
association between these diseases and coronary artery disease has not been totally 
clarified. Similar to previous reports, we did not find an increased risk of coronary 
artery disease in these individuals;18 however, this association was significant in the 
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analysis of a nation-wide, population-based Danish cohort.23 Finally, individuals with 
spondylopathies did not present with significantly higher risk for any of the end-points 
analyzed. 
 
Prevention of cardiovascular disease in chronic immune-mediated inflammatory 
disease 
The most-used treatments for controlling CIID, and particularly rheumatoid arthritis, the 
most thoroughly described, may have antagonistic effects on cardiovascular risk. The 
DMARDs drugs may confer a cardioprotective effect mostly attributed to the inhibition 
of systemic inflammation.24 However, Aviña-Zubieta et al. described a dual effect of 
glucocorticoids on myocardial infarction risk in individuals with rheumatoid arthritis: 
an immediate effect mediated through current dosage and a long-term effect of 
cumulative exposure.25 In addition, del Rincón et al. pointed out that daily doses higher 
than 8 mg were associated with higher cardiovascular and overall mortality in such 
individuals.26 Recently, O’Neill et al. showed in a randomized clinical trial the 
beneficial effect of certain anti-inflammatory treatments that modulate the tumour 
necrosis factor-α pathway (e.g. methortrexate + infliximab), to restore the beneficial 
effects of HDL on the vasculature.27 
To minimize the confounder effect of such variables, Model 2 of the present analysis 
was adjusted for drug use, divided in three categories (DMARDs, anti-inflammatory 
drugs, and non-DMARD non-anti-inflammatory drugs). Indeed, further 
pharmacoepidemiology studies are needed to ascertain the effect of antirheumatic 
treatments in all CIID diagnoses. 
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A reduction in the number of individuals diagnosed with systemic connective tissue 
disorders and rheumatoid arthritis may have a moderate population impact on 
preventing coronary artery disease, stroke and CVD. However, the diagnosis of such 
CIIDs together with an adverse cardiovascular profile may have an additive effect on 
the risk of coronary artery disease and CVD. The most recent European League Against 
Rheumatism (EULAR) guideline promotes a proactive management of cardiovascular 
risk in individuals with inflammatory polyarthritis and spondylopathies. The objective is 
to control not only systemic inflammation, but also cardiovascular risk factors.28 These 
recommendations have also been proposed for individuals with systemic lupus 
erythematosus29 but could probably be extended to individuals with any systemic 
connective tissue disorder. In addition, the development of new tools for the prediction 
of cardiovascular events, which could incorporate CIID activity biomarkers, may help 
to reduce the incidence of such events.24 30 
 
Characteristics and limitations of the study 
Our study has several limitations. To avoid misclassification bias, we used medical 
diagnosis of CIID extracted from SIDIAP, a primary care database. Although this 
source of data may contain underreporting, the validity of SIDIAP coding for ICD-10 
diagnosis of cardiovascular and rheumatic diseases has been documented.10 11 Indeed, 
the results of the sensitivity analyses confirm the robustness of the case-definition. In 
addition, the representativeness of data ensures the generalizability of the results. The 
covariates of the present analysis had missing values (ranging from 9% to 78%) that 
could influence the results. To avoid selection bias, wherever the population with 
missing data differed from those with complete data, we imputed the missing values for 
16 
 
continuous variables instead of excluding records with missing data. The 
appropriateness of performing multiple imputations depends not only on the percentage 
and mechanism of missing values but also on the number of complete observations used 
in the imputation process. In our study, 218,140 complete cases were available to 
impute variables with missing values. Exposure variables (i.e. CIID diagnoses) and 
outcomes did not present missing values. In our study, we analyzed the two most 
frequent single CIID diagnoses (rheumatoid arthritis and systemic lupus erythematosus) 
in the population and in the literature. In addition, we provided broad definitions of 
CIID diagnosis (i.e., inflammatory bowel diseases, inflammatory polyarthropathies, 
systemic connective tissue disorders and spondylopathies). This approach, proposed by 
Dregan et al., allowed for comparison of results.18 Finally, the present analysis did not 
consider variables such as severity or elapsed time between CIID diagnosis and the 
incidence of cardiovascular events or death. Indeed, the use of broad CIID definitions 
may complicate the use of such variables due to the number and the heterogeneity of 
diseases included in every group.  
The results of our study confirm the high cardiovascular risk conferred by previous 
studies exploring CIID incidence with lower sample sizes.4 6-8 22 However, some biases 
inherent to the observational design of the study should be considered. On the one hand, 
additional confounding factors not controlled in the present analysis are likely to play a 
key role in cardiovascular risk of individuals with CIID. On the other hand, the effect of 
cardiovascular and rheumatic disease-specific treatments merits the development of 
pharmacoepidemiology studies considering each CIID’s specific variables to ascertain 







Systemic connective tissue disorders and rheumatoid arthritis were the CIID diagnoses 
with the highest 6-year risk of coronary artery disease or any cardiovascular event and 
the greatest population impact. Diagnosis of inflammatory bowel diseases (i.e. 
ulcerative colitis and Crohn disease) conferred a significant risk and PAF for stroke. 
Regarding overall mortality, all CIID diagnoses except spondylopathies increased 6-
year mortality.  
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Figure 1 Participants flow-chart. CAD: Coronary artery disease. CIID: Chronic 
immune mediate inflammatory disease. CVD: Cardiovascular disease. 
Figure 2 Survival curves for 6-year incidence of coronary artery disease (A), 
cerebrovascular disease (B), cardiovascular disease (C), and overall mortality (D) 
according to CIID diagnoses and in CIID-free population. Log-rank test p-values have 
been computed for each CIID diagnosis and CIID-free individuals.  
Figure 3 Hazard ratios for 6-year incidence of coronary artery disease (A), 
cerebrovascular disease (B), cardiovascular disease (C), and overall mortality (D) 
among participants with CIID diagnosis compared with those without CIID.  
Model 1 has been adjusted by age, sex, smoking status, total cholesterol, HDL 
cholesterol, systolic blood pressure and diastolic blood pressure. Model 2 has been 
further adjusted for statins, hypertensive drugs and rheumatic disease-specific 
treatments divided in 3 categories: DMARDs users, other anti-inflammatory drugs, not 
exposed to any of them.  
Figure 4 Population attributable fraction for 6-year incidence of coronary artery 
disease (A), cerebrovascular disease (B), cardiovascular disease (C), and overall 
mortality (D) for different chronic immune-mediated diseases. Bars are ordered 
according to the magnitude of the population-attributable fraction for each group of 





Table 1 Baseline characteristics of participants according to diagnosis of chronic immune-mediated inflammatory diseases 









N (%) 9544 (1.0) 22 779 (2.3) 4491 (0.5) 2243 (0.2) 952 489 (96.1) 
Age, mean (SD) 56 (14) 60 (12) 63 (14) 55 (12) 52 (13) 
Sex (men), n (%) 4162 (44) 14371 (63) 890 (20) 1185 (53) 446 886 (47) 
Diabetes, n (%) 807 (10) 2806 (13) 437 (11) 205 (10) 61 131 (7) 
Glycemia (mg/dl), median [IQR] 92 [82-104] 95 [85-108] 91 [82-102] 92 [83-104] 91 [82-103] 
Hypertension, n (%) 2760 (29) 9633 (42) 1801 (40) 664 (30) 182 170 (19) 
Systolic blood pressure (mmHg), mean (SD) 129 (16) 133 (17) 131 (17) 129 (16) 128 (16) 
Diastolic blood pressure (mmHg), mean (SD) 77 (10) 78 (10) 76 (9) 77 (10) 77 (10) 
Dyslipidemia, n (%) 2645 (28) 8068 (35) 1493 (33) 581 (26) 174 995 (18) 
Total cholesterol (mg/dl), mean (SD) 206 (37) 208 (37) 208 (37) 207 (37) 206 (36) 
HDL cholesterol (mg/dl), mean (SD) 57 (15) 55 (15) 61 (15) 56 (15) 57 (15) 
LDL cholesterol (mg/dl), mean (SD) 125 (33) 126 (33) 125 (33) 127 (34) 125 (32) 
Triglycerides (mg/dl), median [IQR] 103 [74-143] 113 [81-161] 99 [73-136] 103 [74-145] 98 [71-138] 
Smoker, n (%) 3448 (36) 8763 (38) 998 (22) 921 (41) 294 541 (31) 
Obesity, n (%) 3226 (34) 9361 (41) 1608 (36) 763 (34) 278 919 (29) 
Body mass index, mean (SD) 28.0 (4.8) 28.9 (4.8) 28.1 (4.9) 28.1 (4.7) 27.6 (4.6) 
Statins, n (%) 1246 (13) 3870 (17) 903 (20) 296 (13) 85 201 (9) 
Aspirin, n (%) 425 (4) 1468 (6) 395 (9) 103 (5) 28 281 (3) 
Disease-modifying antirheumatic drugs, n (%) 737 (8) 1248 (5) 592 (13) 121 (5) 2013 (0.2) 
Anti-hypertensive treatment, n (%) 2683 (28) 9006 (40) 1844 (41) 634 (28) 171 004 (18) 
10-year cardiovascular risk (%), median [IQR] 2.4 [1.3-4.4] 3.6 [2.0-6.6] 2.3 [1.4-4.0] 2.7 [1.5-4.9] 2.1 [1.1-3.7] 
CIID, Chronic immune-mediated inflammatory disease; IQR, Interquartile range; SD, Standard deviation 
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Table 2 Annual incidence rates for cardiovascular end-points and overall mortality according to different CIID diagnoses per 1,000 person-year (95% 


















 n Annual incidence  
(95% CI) 
n Annual incidence 
(95% CI) 
n Annual incidence 
(95% CI) 
n Annual incidence 
(95% CI) 





(2.75 to 3.71) 
597 4.61 
(4.24 to 4.98) 
122 4.84 
(3.98 to 5.70) 
43 3.34 
(2.34 to 4.34) 
12 841 2.35  
(2.31 to 2.39) 
Stroke 177 3.28 
(2.80 to 3.77) 
519 3.99 
(3.65 to 4.34) 
118 4.66 
(3.82 to 5.50) 
29 2.24 
(1.43 to 3.06) 
10 665 1.95 




(5.75 to 7.11) 
1090 8.49 
(7.99 to 9.00) 
237 9.49 
(8.28 to 10.70) 
71 5.54 
(4.25 to 6.83) 
23 009 4.24 
(4.18 to 4.29) 
Overall mortality 650 11.96 
(11.04 to 12.88) 
1403 10.69 
(10.13 to 11.25) 
362 14.16 
(12.70 to 15.62)  
95 7.31 
(5.84 to 8.78) 
28 723 5.23  
(5.17 to 5.29) 
CIID, Chronic immune-mediated inflammatory disease 
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Figure 1. 
 
 
26 
 
Figure 2. 
27 
 
Figure 3. 
28 
 
Figure 4. 
 
